Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT07193199

New Technique and Product for Chin Enhancement

A Novel Substrate and Injection Technique for Chin Augmentation

Status
Active Not Recruiting
Phase
N/A
Study type
Interventional
Enrollment
21 (estimated)
Sponsor
Erevna Innovations Inc. · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The use of hyaluronic acid (HA) fillers for soft tissue augmentation offers a valuable treatment modality for the correction of chin retrusion (i.e., when the chin appears to be set back or further back than normal in relation to the rest of the face). Their use is well-tolerated and provides satisfactory aesthetic results by improving facial balance and projection. Although the efficacy of hyaluronic acid HA fillers for chin augmentation has been established, the specific anatomy of the region may lead to adverse events. More specifically, certain fillers with strong integration characteristics may lead to product migration, while others with poor integration characteristics may lead to palpable deformities and distortion of the surrounding injection tissues. Using a filler that has a high concentration of hyaluronic acid, a medium level of firmness and low water absorption may offer an effective option for treating this indication while minimizing certain adverse events. In addition, using consistent, standardized injection techniques can help achieve an ideal result. We believe that the use of a novel HA gel (Revanesse Sculp+) for the chin, with a high concentration of HA, a moderate firmness and low water absorption, will perform better than historical controls with firmer properties in the management of chin retrusion.

Conditions

Interventions

TypeNameDescription
DEVICERevanesse Sculpt+Revanesse Sculpt+ is approved and commercially available for use in Canada and is manufactured by Prollenium Technologies Inc. All study participants will receive Revanesse Sculpt+ for the treatment of mild to severe chin retrusion.

Timeline

Start date
2025-06-02
Primary completion
2026-05-24
Completion
2026-06-24
First posted
2025-09-25
Last updated
2025-09-30

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT07193199. Inclusion in this directory is not an endorsement.